Loading...
•
Sep 30, 2021
Standard Biotool Q3 2021 Earnings Report
Reported a decrease in total revenue due to supply chain issues and APAC regional impacts, with the board reviewing options to maximize stockholder value.
Key Takeaways
Fluidigm Corporation reported a decrease in total revenue for Q3 2021 compared to Q3 2020, primarily due to supply chain constraints and regional impacts in APAC. The company's board is undertaking a review of options to maximize stockholder value. Base product and service revenue saw a slight increase, but the company faced challenges in fulfilling orders, resulting in a significant backlog.
Total revenue was $28.5 million, down from $39.9 million in Q3 2020.
Base product and service revenue increased to $25.6 million from $25.1 million in the same period last year.
GAAP net loss was $13.8 million, compared to a net loss of $6.0 million in Q3 2020.
Non-GAAP net loss was $5.4 million, compared to non-GAAP net income of $2.5 million in Q3 2020.